About Zurex Pharma
Zurex Pharma is a private company based in Middleton, Wisconsin. It has reported $30,074,988 raised in six offerings on Form D since June 2012. Its chief executive is Alexander Kasper.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 14, 2023 | Dec 29, 2023 | $3,779,232of $4.0M target | 14 | $269K | EquityRule 506(b) | Form D ↗ |
| Jun 4, 2020 | Jun 16, 2020 | $7,495,040of $15.0M target | 18 | $416K | EquityRule 506(b) | Form D ↗ |
| May 25, 2018 | Jun 11, 2018 | $2,237,490of $2.9M target | 11 | $203K | EquityRule 506(b) | Form D ↗ |
| Aug 2, 2016 | Aug 11, 2016 | $6,236,068of $8.0M target | 26 | $239K | EquityRule 506(b) | Form D ↗ |
| Jun 23, 2014 | Jul 1, 2014 | $4,127,158of $5.1M target | 13 | $317K | EquityRule 506(b) | Form D ↗ |
| May 17, 2012 | Jun 7, 2012 | $6,200,000fully sold | 11 | $563K | Equity06 | Form D ↗ |
| Total, six offerings | $30,074,988 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Zurex Pharma's Form D filed Dec 29, 2023.
Earlier filings also listed Roy Morgan (executive officer, last listed Jun 2020), Robert Truitt (director, last listed Jun 2020), Michael Liang (director, last listed Jun 2020), Carmine Durham (chief executive officer and director, last listed Jun 2020), Andrew Morgan (executive officer, last listed Jun 2018), Connie Curran (director, last listed Jul 2014), R Morgan (executive officer, last listed Jun 2012) and Gary Lehman (director, last listed Jun 2012).